Systems engineering medicine: Engineering the inflammation response to infectious and traumatic challenges

Journal of the Royal Society Interface

Volumn 7, Issue 48, 2010, Pages 989-1013

  Parker, Robert S ^a,b   Clermont, Gilles ^b,c  

^a University of Pittsburgh   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Dynamic modelling; Haemoadsorption; Inflammation; Model based control; Optimization; Sepsis

Indexed keywords

OPTIMIZATION; PATHOLOGY; SYSTEMS ENGINEERING;

BASIC SCIENCE; DEVICE DESIGN; DYNAMIC MODELLING; INFLAMMATORY RESPONSE; MODEL-BASED CONTROL; OPTIMIZATION TOOLS; PATHOGENIC INFECTIONS; POPULATION VARIABILITY; PROCESS UNDERSTANDING; SYSTEMS BIOLOGY; TREATMENT DESIGN;

PHYSIOLOGICAL MODELS;

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

BIOMEDICAL ENGINEERING; DECISION SUPPORT SYSTEM; DISEASE MODEL; HEMADSORPTION; HUMAN; IMMUNOPATHOGENESIS; INFECTION; INFLAMMATION; INJURY; NONHUMAN; PATHOPHYSIOLOGY; PHENOMENOLOGY; REVIEW; SEPSIS; STOCHASTIC MODEL; SYSTEMS BIOLOGY;

EID: 77954511008     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2009.0517     Document Type: Review

References (179)

1. Abreu, M. T. & Arditi, M. 2004 Innate immunity and toll-like receptors: clinical implications of basic science research. J. Pediatr. 144, 421-429. (doi:10.1016/j.jpeds.2004.01.057)
2. Adalsteinsson, D., McMillen, D. & Elston, T. C. 2004 Biochemical network stochastic simulator (bionets): software for stochastic modeling of biochemical networks. BMC Bioinformatics 5, 24. (doi:10.1186/1471-2105-5-24) (Pubitemid 38751311)
3. Adams, G. L., Manson, R. J., Turner, I., Sindram, D. & Lawson, J. H. 2007 The balance of thrombosis and hemorrhage in surgery. Hematol. Oncol. Clin. North Am. 21, 13-24. (doi:10.1016/j.hoc.2006.11.013)
4. Allgöwer, F., Badgwell, T. A., Qin, J. S., Rawlings, J. B. & Wright, S. J. 1999 Nonlinear predictive control and moving horizon estimation: an introductory overview. Advances in control - highlights of ECC '99, pp. 391-449. London, UK: Springer.
5. Alves-Filho, J. C., Benjamim, C., Tavares-Murta, B. M. & Cunha, F.Q. 2005 Failure of neutrophil migration toward infectious focus in severe sepsis: a critical event for the outcome of this syndrome. Mem. Inst. Oswaldo Cruz. 100(Suppl. 1), 223-226. (doi:10.1590/S0074-02762005000900038)
6. Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J. & Pinsky, M. R. 2001 Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310. (doi:10.1097/00003246-200107000-00002)
7. Annane, D. 2009 Improving clinical trials in the critically ill: unique challenge-sepsis. Crit. Care Med. 37(Suppl. 1), S117-S128. (doi:10.1097/CCM. 0b013e318192078b)
8. Annane, D. et al. 2002 Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288, 862-871. (doi:10.1001/jama.288.7.862)
9. Arkin, A., Ross, J. & McAdams, H. H. 1998 Stochastic kinetic analysis of developmental pathway bifurcation in phage lambda-infected Escherichia coli cells. Genetics 149, 1633-1648. (Pubitemid 28375939)
10. Audoly, S., D'Angio, L., Saccomani, M. P. & Cobelli, C. 1998 Global identifiability of linear compartmental models: a computer algebra algorithm. IEEE Trans. Biomed. Eng. 45, 36-47. (doi:10.1109/10.650350)
11. Audoly, S., Belu, G., D'Angio, L., Saccomani, M. P. & Cobelli, C. 2001 Global identifiability of nonlinear models of biological systems. IEEE Trans. Biomed. Eng. 48, 55-65. (doi:10.1109/10.900248)
12. Auffray, C., Chen, Z. & Hood, L. 2009 Systems medicine: the future of medical genomics and healthcare. Genome Med. 1, 2. (doi:10.1186/gm2)
13. Bakker, J. et al. 2004 Administration of the nitric oxide synthase inhibitor ng-methyl-L-arginine hydrochloride (546c88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit. Care Med. 32, 1-12. (doi:10.1097/01.CCM. 0000105118.66983.19)
14. Beal, S. L. 1984 Population pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metabol. Rev. 15, 173-193. (doi:10.3109/03602538409015064)
15. Beal, S. L. & Sheiner, L. B. 1982 Estimating population kinetics. CRC Crit. Rev. Biomed. Eng. 8, 195-222.
16. Beal, S. L. & Sheiner, L. B. 1992 NONMEM user's guide. NONMEM Project Group. San Francisco, CA: University of California.
17. Bellazzi, R., Nucci, G. & Cobelli, C. 2001 The subcutaneous route: closed-loop and partially closed-loop strategies in insulin dependent diabetes mellitus. IEEE Eng. Med. Biol. 20, 54-64. (doi:10.1109/51.897828)
18. Bellu, G., Saccomani, M. P., Audoly, S. & D'Angio, L. 2007 DAISY: a new software tool to test global identifiability of biological and physiological systems. Comp. Meth. Prog. Biomed. 88, 52-61. (doi:10.1016/j.cmpb.2007.07.002)
19. Bergman, R. N., Phillips, L. S. & Cobelli, C. 1981 Physiologic evaluation of factors controlling glucose tolerance in man. J. Clin. Invest. 68, 1456-1467. (doi:10.1172/JCI110398)
20. Bernard, G. R. et al. 2001 Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709. (doi:10.1056/NEJM200103083441001)
21. Bernard, G. R., Margolis, B. D., Shanies, H. M., Ely, E. W., Wheeler, A. P., Levy, H., Wong, K. & Wright, T. J. 2004 Extended evaluation of recombinant human activated protein C United States trial (Enhance US): a single-arm, phase 3b, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 125, 2206-2216. (doi:10.1378/chest.125.6.2206) (Pubitemid 38788191)
22. Bertrand, C., Ohmi, M., Suzuki, R. & Kado, H. 2001 A probabilistic solution to the meg inverse problem via MCMC methods: the reversible jump and parallel tempering algorithms. IEEE Trans. Biomed. Eng. 48, 533-542. (doi:10.1109/10.918592)
23. Bertsekas, D. P. 1995 Dynamic programming and optimal control, vols 1 and 2. Belmont, MA: Athena Scientific.
24. Beyer, M., Steinhoff, M., Anagnostopoulos, I., Assaf, C. & Sterry, W. 2009 Hepatosplenic T-cell lymphomas and therapy with TNF-alpha-blocking biologics: a risk for psoriasis patients? J. Dtsch. Dermatol. Ges. 7, 191-194. (doi:10.1111/j.1610-0387.2008.06961.x)
25. Blaha, J. et al. 2009 Comparison of three protocols for tight glycemic control in cardiac surgery patients. Diabetes Care 32, 757-761. (doi:10.1007/s00134-008-1236-z)
26. Blinov, M. L., Faeder, J. R., Goldstein, B. & Hlavacek, W. S. 2004 BioNetGen: software for rule-based modeling of signal transduction based on the interactions of molecular domains. Bioinformatics 20, 3289-3291. (doi:10.1093/bioinformatics/bth378) (Pubitemid 39619231)
27. Bolie, V. W. 1961 Coefficients of normal blood glucose regulation. J. Appl. Physiol. 16, 783-788.
28. Bondia, J., Dassau, E., Zisser, H., Calm, R., Vehí, J., Jovanovic, L. & Doyle III, F. J. 2009 Coordinated basal-bolus infusion for tighter postprandial glucose control in insulin pump therapy. J. Diabetes Sci. Technol. 3, 89-97.
29. Bone, R. C. 1996 Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann. Intern. Med. 125, 680-687.
30. Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L. & Montori, V. 2006 Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285. (doi:10.1001/jama.295.19.2275)
31. Boujoukos, A. J., Martich, G. D., Supinski, E. & Suffredini, A. F. 1993 Compartmentalization of the acute cytokine response in humans after intravenous endotoxin administration. J. Appl. Physiol. 74, 3027-3033.
32. Brealey, D., Karyampudi, S., Jacques, T. S., Novelli, M., Stidwill, R., Taylor, V., Smolenski, R. T. & Singer, M. 2004 Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R491-R497. (doi:10.1152/ajpregu.00432.2003)
33. Buras, J. A., Holzmann, B. & Sitkovsky, M. 2005 Animal models of sepsis: setting the stage. Nat. Rev. Drug Discov. 4, 854-865. (doi:10.1038/nrd1854)
34. Camilleri, M. 2007 Anti-TNF antibodies for Crohn's disease. N. Engl. J. Med. 357, 1662. (doi:10.1056/NEJMc072381)
35. Carson, E. & Cobelli, C. (eds) 2001 Modelling methodology for physiology and medicine. San Diego, CA: Academic Press.
36. Carter, J. D., Valeriano, J. & Vasey, F. B. 2003 Crohn disease worsened by Anakinra administration. J. Clin. Rheumatol. 9, 276-277. (doi:10.1097/01.RHU.0000081265.06408.e4)
37. Chang, R. W. & Bihari, D. J. 1994 Outcome prediction for the individual patient in the ICU. Unfallchirurgica 97, 199-204.
38. Chen, H. S. & Gross, J. F. 1979 Physiologically based pharmacokinetic models for anticancer drugs. Cancer Chemother. Pharmacol. 2, 85-94. (doi:10.1007/BF00254079)
39. Chiang, R. Y. & Safonov, M. G. 1992 Robust control toolbox. Natick, MA: The Mathworks, Inc.
40. Chow, C. C. et al. 2005 The acute inflammatory response in diverse shock states. Shock 24, 74-84. (doi:10.1097/01.shk.0000168526.97716.f3)
41. Clermont, G. et al. 2004a Dynamic microsimulation to model multiple outcomes in cohorts of critically ill patients. Intens. Care Med. 30, 2237-2244. (doi:10.1007/s00134-004-2456-5)
42. Clermont, G. et al. 2004b In silico design of clinical trials: a method coming of age. Crit. Care Med. 32, 2061-2070.
43. Clevers, H. 2004 At the crossroads of inflammation and cancer. Cell 118, 671-674. (doi:10.1016/j.cell.2004.09.005)
44. Cobb, J. P. et al. 2005 Application of genome-wide expression analysis to human health and disease. Proc. Natl Acad. Sci. USA 102, 4801-4806. (doi:10.1073/pnas.0409768102)
45. Cobelli, C., Toffolo, G. M., Dalla Man, C., Campioni, M., Denti, P., Caumo, A., Butler, P. & Rizza, R. 2007 Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am. J. Physiol. Endocrinol. Metab. 293, E1-E15. (doi:10.1152/ajpendo.00421.2006)
46. Coleman, T. G., Granger, H. J. & Guyton, A. C. 1971 Whole-body circulatory autoregulation and hypertension. Circ. Res. 28(Suppl. 87), II76-II87.
47. Cordingley, J. J. et al. 2009 Intensive insulin therapy: Enhanced model predictive control algorithm versus standard care. Intens. Care Med. 35, 123-128.
48. Daoutidis, P. & Henson, M. A. 2002 Dynamics and control of cell populations in continuous bioreactors. In Proc. CPC VI, Tucson, AZ, January 2001. AIChE Symposia Series. Austin, TX: CACHE Corporation.
49. D'Argenio, D. Z. & Schumitzky, A. 1997 ADAPT II users guide: pharmacokinetic and pharmacodynamic systems analysis software. Los Angeles, CA: Biomedical Simulations Resource, University of Southern California.
50. Daun, S., Rubin, J., Vodovotz, Y. V., Roy, A., Parker, R. S. & Clermont, G. 2008 An ensemble of models of the acute inflammatory response to bacterial lipopolysaccharide in rats: results from parameter space reduction. J. Theor. Biol. 253, 843-853.
51. Day, J., Rubin, J., Vodovotz, Y., Chow, C. C., Reynolds, A. & Clermont, G. 2006a A reduced mathematical model of the acute inflammatory response. II. Capturing scenarios of repeated endotoxin administration. J. Theor. Biol. 242, 237-256. (doi:10.1016/j.jtbi.2006.02.015)
52. Day, J. D., Rubin, J., Florian, J., Parker, R. P. & Clermont, G. 2006b Modulating inflammation using nonlinear model predictive control. J. Crit. Care 21, 349-350.
53. Dellinger, R. P. et al. 2008 Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intens. Care Med. 34, 17-60. (doi:10.1007/s00134-007-0934-2)
54. Dhainaut, J. F. et al. 2003 Drotrecogin alfa (activated) (recombinant human activated protein c) reduces host coagulopathy response in patients with severe sepsis. Thromb. Haemost. 90, 642-653.
55. Dileo, M. V., Kellum, J. A. & Federspiel, W. J. 2009 A simple mathematical model of cytokine capture using a hemoadsorption device. Ann. Biomed. Eng. 37, 222-229. (doi:10.1007/s10439-008-9587-8)
56. Domach, M. M. & Shuler, M. L. 1984 A finite representation model for an asynchronous culture of E. coli. Biotech. Bioeng. 26, 877-884. (doi:10.1002/bit.260260810)
57. Dombrovskiy, V. Y., Martin, A. A., Sunderram, J. & Paz, H. L. 2007 Occurrence and outcomes of sepsis: influence of race. Crit. Care Med. 35, 763-768. (doi:10.1097/01. CCM.0000256726.80998.BF)
58. Doyle III, F. J. & Stelling, J. 2006 Systems interface biology. J. R. Soc. Interface 22, 603-616. (doi:10.1098/rsif.2006.0143)
59. Doyle III, F. J., Seborg, D., Parker, R. S., Bequette, B. W., Jeffrey, A., Xia, X., Craig, I. & McAvoy, T. J. 2007 A tutorial on biomedical process control. J. Proc. Cont. 17, 571-594. (doi:10.1016/j.jprocont.2007.01.012)
60. Dua, P., Doyle III, F. J. & Pistikopoulos, E. N. 2009 Multi-objective blood glucose control for type 1 diabetes. Med. Biol. Eng. Comput. 47, 343-352. (doi:10.1007/s11517-009-0453-0)
61. Dyson, A. & Singer, M. 2009 Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit. Care Med. 37(Suppl. 1), S30-S37. (doi:10.1097/CCM.0b013e3181922bd3)
62. Eichacker, P. Q. et al. 2002 Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am. J. Respir. Crit. Care Med. 166, 1197-1205. (doi:10.1164/rccm.200204-302OC)
63. Esmon, C. T. 2004 Crosstalk between inflammation and thrombosis. Maturitas 47, 305-314. (doi:10.1016/j.maturitas.2003.10.015)
64. Faeder, J. R., Blinov, M. L. & Hlavacek, W. S. 2009 Rulebased modeling of biochemical systems with BioNetGen. Methods Mol. Biol. 500, 113-167.
65. Finegood, D. T. & Tzur, D. 1996 Reduced glucose effectiveness associated with reduced insulin release: an artifact of the minimal-model method. Am. J. Physiol. 271, E485-E495.
66. Fink, M. P. 1990 Leaky gut hypothesis: a historical perspective. Crit. Care Med. 18, 579-580.
67. Fink, M. P. 2008 Animal models of sepsis and its complications. Kidney Int. 74, 991-993. (doi:10.1038/ki.2008.442)
68. Fiorino, G., Allez, M., Malesci, A. & Danese, S. 2009 Review article: anti-TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 29, 921-927. (doi:10.1111/j.1365-2036.2009.03955.x)
69. Flierl, M. A., Rittirsch, D., Huber-Lang, M. S., Sarma, J. V. & Ward, P. A. 2008 Molecular events in the cardiomyopathy of sepsis. Mol. Med. 14, 327-336.
70. Florian Jr, J. A. et al. 2007 A physiologically-based pharmacokinetic (PBPK) and pharmacodynamic model of docetaxel (Doc) and neutropenia in humans. In American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2007. Alexandria, VA: American Society of Oncology.
71. Food and Drug Administration. 2004 Innovation or stagnation: challenge and opportunity on the critical path to new medical products. Technical report. See http:// www.fda.gov/downloads/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf.
72. Fornier, M. & Norton, L. 2005 Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res. 7, 64-69. (doi:10.1186/bcr1007)
73. Gillespie, D. T. 1977 Exact stochastic simulation of coupled chemical reactions. J. Phys. Chem. 8, 2340-2361. (doi:10.1021/j100540a008)
74. Gillespie, D. T. 2000 The chemical langevin equation. J. Chem. Phys. 113, 297-306. (doi:10.1063/1.481811)
75. ∞-error bounds. Int. J. Control 39, 1145-1193. (doi:10.1080/00207178408933239)
76. Gneiting, T. & Raftery, A. E. 2005 Atmospheric science: weather forecasting with ensemble methods. Science 310, 248-249. (doi:10.1126/science. 1115255)
77. Gopinath, R., Bequette, B. W., Roy, R. J., Kaufman, H. & Yu, C. 1995 Issues in the design of a multirate model-based controller for a nonlinear drug infusion system. Biotechnol. Prog. 11, 318-332. (doi:10.1021/bp00033a013)
78. Granger, D. N., Rutili, G. & McCord, J. M. 1981 Superoxide radicals in feline intestinal ischemia. Gastroenterology 81, 22-29. (Pubitemid 11078477)
79. Hancioglu, B. 2007 Mathematical modeling of virus dynamics in immunology. PhD thesis, Department of Mathematics, University of Pittsburgh, PA. See http://etd.library.pitt. edu/ETD/available/etd-12072007-105848/unrestricted/ 07Handissertation.pdf.
80. Harrold, J. M. & Parker, R. S. 2009 Clinically relevant cancer chemotherapy dose scheduling via mixed-integer optimization. Comput. Chem. Eng. 33, 2042-2054.
81. Henson, M. A. 2003 Dynamic modeling of microbial cell populations. Curr. Opin. Biotechnol. 14, 460-467. (doi:10.1016/S0958-1669(03)00104-6)
82. Hickey, M. J. & Kubes, P. 2009 Intravascular immunity: the host-pathogen encounter in blood vessels. Nat. Rev. Immunol. 9, 364-375. (doi:10.1038/nri2532)
83. Hovorka, R., Chassin, L. J., Ellmeer, M., Plank, J. & Wilinska, M. E. 2008 A simulation model of glucose regulation in the critically ill. Physiol. Meas. 29, 959-978. (doi:10.1088/0967-3334/29/8/008)
84. Huang, H. P., Lee, M.W. & Chen, C. L. 2001 A system of procedures for identification of simple models using transient step response. Ind. Eng. Chem. Res. 40, 1903-1915. (doi:10.1021/ie0005001)
85. International Life Sciences Institute. 1994 Risk Science Institute Working Group on physiological parameters. Physiological parameter values for PBPK models. A report prepared by the International Life Sciences Institute, Risk Science Institute under a cooperative agreement with the US Environmental Protection Agency, Office of Health and Environmental Assessment.
86. Joyce, D. E. & Grinnell, B. W. 2002 Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappab. Crit. Care Med. 30(Suppl. 5), S288-S293. (doi:10.1097/00003246-200205001-00019)
87. Jusko, J. W. & Ko, H. C. 1994 Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56, 406-419.
88. Kellum, J. A. 2003 Hemoadsorption therapy for sepsis syndromes. Crit. Care Med. 31, 323-324. (doi:10.1097/00003246-200301000-00060)
89. Kellum, J. A. et al. 2007 Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of sepsis (genims) study. Arch. Intern. Med. 167, 1655-1663. (doi:10.1001/archinte.167.15.1655)
90. Kinasewitz, G. T. et al. 2004 Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit. Care 8, R82-R90. (doi:10.1186/cc2459)
91. Kitano, H. 2002 Systems biology: a brief overview. Science 295, 1662-1664. (doi:10.1126/science.1069492)
92. Kuepfer, L., Peter, M., Sauer, U. & Stelling, J. 2007 Ensemble modeling for analysis of cell signaling dynamics. Nat. Biotechnol. 25, 1001-1006. (doi:10.1038/nbt1330)
93. Kumar, R., Clermont, G., Vodovotz, Y. & Chow, C. C. 2004 The dynamics of acute inflammation. J. Theor. Biol. 230, 145-155. (doi:10.1016/j.jtbi.2004. 04.044)
94. Kumar, A. et al. 2006 Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34, 1589-1596. (doi:10.1097/01.CCM. 0000217961.75225.E9)
95. Kumareswaran, K., Evans, M. L. & Hovorka, R. 2009 Artificial pancreas: an emerging approach to treat type 1 diabetes. Expert Rev. Med. Dev. 6, 401-410. (doi:10.1586/erd.09.23)
96. Lee, E. K. & Zaider, M. 2008 Operations research advances cancer therapeutics. Interfaces 38, 5-25. (doi:10.1287/inte.1070.0327)
97. Lee, J. H., Gelormino, M. S. & Morari, M. 1992 Model predictive control of multi-rate sampled-data systems: a state-space approach. Int. J. Control 55, 153-191. (doi:10.1080/00207179208934231)
98. Levy, M. M. et al. 2003 2001 sccm/esicm/accp/ats/sis international sepsis definitions conference. Crit. Care Med. 31, 1250-1256. (doi:10.1097/01.CCM. 0000050454.01978.3B)
99. Lipiner-Friedman, D. et al. 2007 Adrenal function in sepsis: the retrospective corticus cohort study. Crit. Care Med. 35, 1012-1018. (doi:10.1097/01.CCM.0000259465.92018.6E)
100. Lipniacki, T. & Kimmel, M. 2007 Deterministic and stochastic models of NF kappa B pathway. Cardiovasc. Toxicol. 7, 215-234. (doi:10.1007/s12012-007- 9003-x)
101. Lipniacki, T., Hat, B., Faeder, J. R. & Hlavacek, W. S. 2008 Stochastic effects and bistability in T cell receptor signaling. J. Theor. Biol. 254, 110-122. (doi:10.1016/j.jtbi.2008.05.001)
102. Ljung, L. 1999 System identification: theory for the user, 2nd edn. Upper Saddle River, NJ: Prentice Hall PTR.
103. Ma, A. C. & Kubes, P. 2008 Platelets, neutrophils, and neutrophil extracellular traps (nets) in sepsis. J. Thromb. Haemost. 6, 415-420. (doi:10.1111/j.1538-7836.2007.02865.x)
104. Mahfouf, M., Abbod, M. F. & Linkens, D. A. 2001 A survey of fuzzy logic monitoring and control utilisation in medicine. Artif. Intell. Med. 21, 27-42. (doi:10.1016/S0933-3657(00)00072-5)
105. Maiti, R. & Agrawal, N. K. 2007 Atherosclerosis in diabetes mellitus: role of inflammation. Ind. J. Med. Sci. 61, 292-306. (doi:10.4103/0019-5359. 32098)
106. Mantzaris, N. V., Daoutidis, P. & Srienc, F. 2001a Numerical solution of multi-variable cell population balance models. I. Finite difference methods. Comput. Chem. Eng. 25, 1411-1440. (doi:10.1016/S0098-1354(01)00709-8)
107. Mantzaris, N. V., Daoutidis, P. & Srienc, F. 2001b Numerical solution of multi-variable cell population balance models. II: Spectral models. Comput. Chem. Eng. 25, 1441-1462. (doi:10.1016/S0098-1354(01)00710-4)
108. Mantzaris, N. V., Daoutidis, P. & Srienc, F. 2001c Numerical solution of multi-variable cell population balance models. III: Finite element methods. Comput. Chem. Eng. 25, 1463-1481. (doi:10.1016/S0098-1354(01)00711-6)
109. Marshall, J. C. 2000 Clinical trials of mediator-directed therapy in sepsis: what have we learned? Intensive Care Med. 26(Suppl. 1), 75-83. (doi:10.1007/s001340051122)
110. Marshall, J. C. 2004 Through a glass darkly: the brave new world of in silico modeling. Crit. Care Med. 32, 2157-2159. (doi:10.1097/01.CCM.0000142935. 34916.B5)
111. Marshall, J. C., Vincent, J. L., Fink, M. P., Cook, D. J., Rubenfeld, G., Foster Jr, D., Fisher, C. J., Faist, E. & Reinhart, K. 2003 Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, 25-26 October 2000. Crit. Care Med. 31, 1560-1567. (doi:10.1097/01.CCM.0000065186.67848.3A)
112. Martin, G. S., Mannino, D. M., Eaton, S. & Moss, M. 2003 The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554. (doi:10.1056/NEJMoa022139)
113. Martin, R. & Teo, K. L. 1994 Optimal control of drug administration in cancer chemotherapy. River Edge, NJ: World Scientific.
114. Martin, R. B. 1992 Optimal control drug scheduling of cancer chemotherapy. Automatica 28, 1113-1123. (doi:10.1016/0005-1098(92)90054-J)
115. Matzinger, P. 2002 An innate sense of danger. Ann. N.Y. Acad. Sci. 961, 341-342. (doi:10.1111/j.1749-6632.2002.tb03118.x)
116. Meldrum, K. K., Metcalfe, P., Leslie, J. A., Misseri, R., Hile, K. L. & Meldrum, D. R. 2006 TNF-alpha neutralization decreases nuclear factor-kappa b activation and apoptosis during renal obstruction. J. Surg. Res. 131, 182-188. (doi:10.1016/j.jss.2005.11.581)
117. Moore, B. C. 1981 Principal component analysis in linear systems: controllability, observability, and model reduction. IEEE Trans. Aut. Control AC-26, 17-32.
118. Morari, M. 1994 Model predictive control: multivariable control technique of choice in the 1990s? In IFAC Symp. on Advanced Control of Chemical Processes, Kyoto, Japan, May 1994, pp. 1-16. Oxford, UK: Pergamon.
119. Morari, M. & Ricker, N. L. 1994 Model predictive control toolbox. Natick, MA: The MathWorks, Inc.
120. Morari, M. & Zafiriou, E. 1989 Robust process control. Princeton, NJ: Prentice-Hall.
121. Muske, K. R. & Rawlings, J. B. 1993 Model predictive control with linear models. AIChE J. 39, 262-287. (doi:10.1002/aic.690390208)
122. Nemzek, J. A., Hugunin, K. M. & Opp, M. R. 2008 Modeling sepsis in the laboratory: merging sound science with animal well-being. Comput. Med. 58, 120-128.
123. Nucci, G. & Cobelli, C. 2000 Models of subcutaneous insulin kinetics. A critical review. Comput. Method. Prog. Biomed. 62, 249-257. (doi:10.1016/S0169-2607(00)00071-7)
124. Ogunnaike, B. A. 2006 Elucidating the digital control mechanism for DNA damage repair with the pp53-Mdm2 system: single cell data analysis and ensemble. J. R. Soc. Interface 3, 175-184. (doi:10.1098/rsif.2005.0077)
125. Osuchowski, M. F., Connett, J., Welch, K., Granger, J. & Remick, D. G. 2009 Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis. Crit. Care Med. 37, 1567-1573. (doi:10.1097/CCM.0b013e31819df06b)
126. Panacek, E. A. et al. 2004 Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody f(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit. Care Med. 32, 2173-2182.
127. Parker, R. S. & Doyle III, F. J. 2001 Control-relevant modeling in drug delivery. Adv. Drug Deliv. Rev. 48, 211-228. (doi:10.1016/S0169-409X(01) 00114-4)
128. Parker, R. S., Doyle III, F. J. & Peppas, N. A. 1999 A model-based algorithm for blood glucose control in type I diabetic patients. IEEE Trans. Biomed. Eng. 46, 148-157. (doi:10.1109/10.740877)
129. Parker, R. S., Ward, J. H., Peppas, N. A. & Doyle III, F. J. 2000 Robust H1 glucose control in diabetes using a physiological model. AIChE J. 46, 2537-2549. (doi:10.1002/aic.690461220)
130. Pedersen, M. G., Corradin, A., Toffolo, G. M. & Cobelli, C. 2008 A subcellular model of glucose-stimulated pancreatic insulin secretion. Phil. Trans. A Math. Phys. Eng. Sci. 366, 3525-3543.
131. Pfeffer, K. et al. 1993 Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73, 457-467.
132. Plank, J. et al. 2006 Multicentric, randomized, controlled trial to evaluate blood glucose control by the model predictive control algorithm versus routine glucose management protocols in intensive care unit patients. Diabetes Care 29, 271-276. (doi:10.2337/diacare.29.02.06.dc05-1689)
133. Polisetty, P. K., Voit, E. O. & Gatzke, E. P. 2006 Identification of metabolic system parameters using global optimization methods. Theor. Biol. Med. Model. 3, 4. (doi:10.1186/1742-4682-3-4)
134. Polpitiya, A. D., McDunn, J. E., Burykin, A., Ghosh, G. K. & Cobb, J. P. 2009 Using systems biology to simplify complex disease: immune cartography. Crit. Care Med. 37(Suppl. 1), S16-S21.
135. Prince, J. M. et al. 2006 In silico and in vivo approach to elucidate the inflammatory complexity of cd14-deficient mice. Mol. Med. 12, 88-96.
136. Punzi, L., Podswiadek, M., Sfriso, P., Oliviero, F., Fiocco, U. & Todesco, S. 2007 Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmune Rev. 6, 524-528. (doi:10.1016/j.autrev.2006.12. 003)
137. Qin, S. J. & Badgwell, T. A. 1999 An overview of nonlinear MPC applications. In Nonlinear model predictive control: assessment and future directions (eds F. Allgöwer & A. Zheng). Basel, Switzerland: Birkhäuser.
138. Quon, M. J., Cochran, C., Taylor, S. I. & Eastman, R. C. 1994 Non-insulin-mediated glucose disappearance in subjects with IDDM. Discordance between experimental results and minimal model analysis. Diabetes 43, 890-896. (doi:10.2337/diabetes.43.7.890)
139. Ramkrishna, D. 2000 Population balances: theory and applications to particulate systems in engineering. San Diego, CA: Academic Press.
140. Rathinam, M., Petzold, L. R., Cao, Y. & Gillespie, D. T. 2003 Stiffness in stochastic chemically reacting systems: the implicit tau-leaping method. J. Chem. Phys. 119, 12 784-12 794.
141. Rawlings, J. B., Meadows, E. S. & Muske, K. R. 1994 Nonlinear model predictive control: a tutorial and survey. In IFAC Symp. on Advanced Control of Chemical Processes, Kyoto, Japan, pp. 203-214.
142. Remick, D. G. 2003 Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr. Pharm. Des. 9, 75-82. (doi:10.2174/1381612033392567)
143. Resource Facility for Population Kinetics. 2008 See http:// depts.washington.edu/rfpk/. (accessed 17 March 2008).
144. Reynolds, A. M. 2008 Mathematical models of acute inflammation and a full lung model of gas exchange under inflammatory stress. PhD thesis, Department of Mathematics, University of Pittsburgh, PA. See http:// etd.library.pitt.edu/ ETD/available/etd-06032008-223454/restricted/Reynolds-Angela-thesis-July-20.pdf.
145. Reynolds, A. M., Rubin, J., Clermont, G. & Ermentrout, B. 2006 A reduced mathematical model of the acute inflammatory response. I. Derivation of the model and analysis of anti-inflammation. J. Theor. Biol. 242, 220-236. (doi:10.1016/j.jtbi.2006.02.016)
146. Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E. & Tomlanovich, M. 2001 Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 345, 1368-1377. (doi:10.1056/NEJMoa010307)
147. Rivers, E. P., Kruse, J. A., Jacobsen, G., Shah, K., Loomba, M., Otero, R. & Childs, E. W. 2007 The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock. Crit. Care Med. 35, 2016-2024.
148. Roy, A. 2008 Dynamic modeling of free fatty acid, glucose, and insulin during rest and exercise in insulin dependent diabetes mellitus patients. PhD thesis, Department of Chemical and Petroleum Engineering, University of Pittsburgh, PA.
149. Roy, A. & Parker, R. S. 2006 Dynamic modeling of free fatty acids, glucose, and insulin: An extended minimal model. Diabetes Tech. Theraput. 8, 617-626. (doi:10.1089/dia.2006.8.617)
150. Roy, A. & Parker, R. S. 2007 Dynamic modeling of exercise effects on plasma glucose and insulin levels. J. Diabetes Sci. Tech. 1, 338-347.
151. Salluh, J. I. & Bozza, P. T. 2008 Biomarkers of sepsis: lost in translation? Crit. Care Med. 36, 2192-2194. (doi:10.1097/CCM.0b013e31817c0cd8)
152. Sands, K. E. et al. 1997 Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA 278, 234-240. (doi:10.1001/jama.278.3.234)
153. Sappington, P. L., Yang, R., Yang, H., Tracey, K. J., Delude, R. L. & Fink, M. P. 2002 Hmgb1 b box increases the permeability of caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 123, 790-802. (doi:10.1053/gast.2002.35391) (Pubitemid 34977085)
154. Sharshar, T., Leclerc, F. & Annane, D. 2006 Vasopressin in sepsis: a world of complexity. Pediatr. Crit. Care Med. 7, 281-282. (doi:10.1097/01.PCC. 0000216439.33312.F2)
155. Sheiner, L. B. & Beal, S. L. 1980 Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J. Pharmacokinet. Biopharm. 8, 553-571. (doi:10.1007/BF01060053)
156. Sheiner, L. B. & Ludden, T. M. 1992 Population pharmacokinetics/ dynamics. Annu. Rev. Pharmacol. Toxicol. 32, 185-209.
157. Shuler, M. L. 1999 Single-cell models: promise and limitations. J. Biotechnol. 71, 225-228. (doi:10.1016/S0168-1656(99)00024-3)
158. Skogestad, S. & Postlethwaite, I. 1996 Multivariable feedback control. New York, NY: John Wiley & Sons.
159. Sorensen, J. T. 1985 A physiologic model of glucose metabolism in man and its use to design and assess improved insulin therapies for diabetes. PhD thesis, Department of Chemical Engineering, MIT, MA.
160. Steil, G. M., Murray, J., Bergman, R. N. & Buchanan, T. A. 1994 Repeatability of insulin sensitivity and glucose effectiveness from the minimal model - implications for study design. Diabetes 43, 1365-1371. (doi:10.2337/diabetes.43.11.1365)
161. Sweeney, D. A., Danner, R. L., Eichacker, P. Q. & Natanson, C. 2008 Once is not enough: clinical trials in sepsis. Intens. Care Med. 34, 1955-1960. (doi:10.1007/s00134-008-1274-6)
162. Teorell, T. 1937a Kinetics of distribution of substances administered to the body I. Arch. Int. Pharma. Ther. 57, 202-225.
163. Teorell, T. 1937b Kinetics of distribution of substances administered to the body II. Arch. Int. Pharma. Ther. 57, 226-240.
164. US EPA. 1984 Office of Health and Environmental Assessment by the International Life Sciences Institute. Physiological parameter values for pbpk models.
165. Wada, D. R. & Ward, D. S. 1994 The hybrid model: a new pharmacokinetic model for computer-controlled infusion pumps. IEEE Trans. Biomed. Eng. 41, 134-142. (doi:10.1109/10.284924)
166. Watson, D. et al. 2004 Cardiovascular effects of the nitric oxide synthase inhibitor ng-methyl-l-arginine hydrochloride (546c88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit. Care Med. 32, 13-20. (doi:10.1097/01.CCM.0000104209.07273.FC)
167. Watson, R. S., Carcillo, J. A., Linde-Zwirble, W. T., Clermont, G., Lidicker, J. & Angus, D. C. 2003 The epidemiology of severe sepsis in children in the united states. Am. J. Resp. Crit. Care Med. 167, 695-701. (doi:10. 1164/rccm.200207-682OC)
168. Waugh, J. & Perry, C. M. 2005 Anakinra: a review of its use in the management of rheumatoid arthritis. BioDrugs 19, 189-202. (doi:10.2165/00063030- 200519030-00005)
169. Weber, K. M., Martin, I. K., Best, J. D., Alford, F. P. & Boston, R. C. 1989 Alternative method for minimal model analysis of intravenous glucose tolerance data. Am. J. Physiol. 256, E524-535.
170. Weissman, I. L. & Shizuru, J. A. 2008 The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. Blood 112, 3543-3553. (doi:10.1182/blood-2008-08-078220)
171. Wolkenhauer, O., Ullah, M., Kolch, W. & Cho, K. H. 2004 Modeling and simulation of intracellular dynamics: choosing an appropriate framework. IEEE Trans. Nanobioscience 3, 200-207. (doi:10.1109/TNB.2004.833694)
172. Wyss-Coray, T. 2006 Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12, 1005-1015.
173. Yaffe, M. B. & Fink, M. P. 2000 Cellular signaling in critical care-putting the pieces together. Crit. Care Med. 28(Suppl. 4), 1-2. (doi:10.1097/00003246-200004001-00001)
174. Ye, X., Chu, J., Zhuang, Y. & Zhang, S. 2005 Multi-scale methodology: a key to deciphering systems biology. Front Biosci. 10, 961-965. (doi:10.2741/1590)
175. Yue, H., Brown, M., Knowles, J., Wang, H., Broomhead, D. S. & Kell, D. B. 2006 Insights into the behavior of systems biology models from dynamics sensitivity and identifiability analysis: a case study of an NF- κ B signalling pathway. Mol. Biosyst. 2, 640-649. (doi:10.1039/b609442b)
176. Zafiriou, E. & Chiou, H.-W. 1993 Output constraint softening for SISO model predictive control. In Proc. American Control Conf., San Francisco, CA, pp. 372-376. Picataway, NJ: IEEE Press.
177. Zamamiri, A. M., Zhang, Y., Henson, M. A. & Hjortsø, M. A. 2002 Dynamics analysis of an age distribution model of oscillating yeast cultures. Chem. Eng. Sci. 57, 2169-2181. (doi:10.1016/S0009-2509(02)00109-4)
178. Zenker, S., Rubin, J. & Clermont, G. 2007 From inverse problems in mathematical physiology to quantitative differential diagnoses. PLoS Comput. Biol. 3, e204 (doi:10.1371/journal.pcbi.0030204).
179. Zurakowski, R. & Teel, A. R. 2006 A model predictive control based scheduling method for HIV therapy. J. Theor. Biol. 238, 368-382. (doi:10.1016/j.jtbi.2005.05.004)